Cambridge Journals Online

Cambridge Journals Online
Skip to content
The International Journal of Neuropsychopharmacology (2004), 7 : 501-506 Cambridge University Press
Copyright © 2004 Collegium Internationale Neuropsychopharmacologicum
doi:10.1017/S1461145704004699
Published online by Cambridge University Press 08 Nov 2004


Brief Report

Association of the C(–1019)G 5-HT1A functional promoter polymorphism with antidepressant response


Sylvie Lemonde a1, Lisheng Du a2, David Bakish a2, Pavel Hrdina a2 and Paul R. Albert a1c1
a1 Ottawa Health Research Institute (Neuroscience), University of Ottawa, Departments of Medicine and Cellular and Molecular Medicine, Ottawa, Canada, K1H 8M5
a2 Institute of Mental Health Research, Royal Ottawa Hospital, Ottawa, Canada, K1Z 7K4

Article author query
lemonde s   [PubMed] [Google Scholar
du l   [PubMed] [Google Scholar
bakish d   [PubMed] [Google Scholar
hrdina p   [PubMed] [Google Scholar
albert pr   [PubMed] [Google Scholar

Abstract

Antidepressants, such as serotonin or noradrenaline reuptake inhibitors (e.g. fluoxetine, nefadozone) or 5-HT1A agonists (flibanserin), desensitize the 5-HT1A autoreceptor, which may contribute to their clinical efficacy. The 5-HT1A receptor gene is repressed by NUDR/DEAF-1 in raphe cells at the C-, but not at the G-allele of the C(–1019)G polymorphism that is associated with major depression and suicide. Depressed patients (n=118) were treated with antidepressants including fluoxetine or nefadozone combined with pindolol or flibanserin alone. The severity of depression was assesssed using the Hamilton Rating Scale for Depression. Although patients had similar severity initially, those with the homozygous G(–1019) genotype responded significantly less to flibanserin (p=0.039) and in pooled antidepressant treatment groups (p=0.0497) and were approximately twice as likely to be non-responders as those with the C(–1019)C genotype. These results implicate the C(–1019)G 5-HT1A gene polymorphism as a potential marker for antidepressant response, suggesting a role for repression of the 5-HT1A gene.

(Received March 17 2004)
(Reviewed July 7 2004)
(Revised July 20 2004)
(Accepted August 1 2004)


Key Words: flibanserin; mutation; pharmacogenetics; transcription.

Correspondence:
c1 Dr P. R. Albert, Ottawa Health Research Institute (Neuroscience), University of Ottawa, Departments of Medicine and Cellular and Molecular Medicine, 451 Smyth Road, Ottawa, Canada, K1H 8M5. Tel.: (613) 562-5800 (ext. 8307) Fax: (613) 562-5403 E-mail: palbert@uottawa.ca


back to top
Cambridge University Press